Strs Ohio Buys New Shares in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Strs Ohio has invested approximately $636,000 in Aurinia Pharmaceuticals by acquiring 79,100 shares, representing about 0.06% ownership in the company.
• Aurinia Pharmaceuticals has recently experienced positive analyst ratings, with a consensus target price of $13.00 and a "buy" rating from multiple research firms.
• Company insiders have increased their holdings, including Director Kevin Tang, who purchased 1,000,000 shares for over $10 million, boosting his stake by nearly 10%.

Strs Ohio purchased a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 79,100 shares of the biotechnology company's stock, valued at approximately $636,000. Strs Ohio owned about 0.06% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Deutsche Bank AG increased its position in Aurinia Pharmaceuticals by 54.8% during the fourth quarter. Deutsche Bank AG now owns 142,869 shares of the biotechnology company's stock worth $1,283,000 after acquiring an additional 50,575 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Aurinia Pharmaceuticals by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,314 shares of the biotechnology company's stock worth $685,000 after acquiring an additional 2,887 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in Aurinia Pharmaceuticals during the first quarter worth about $86,000. GAMMA Investing LLC increased its position in Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after acquiring an additional 1,744 shares during the period. Finally, Vident Advisory LLC bought a new position in Aurinia Pharmaceuticals during the first quarter worth about $232,000. Institutional investors and hedge funds own 36.83% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AUPH. Royal Bank Of Canada raised their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. HC Wainwright reissued a "buy" rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $13.00.

Insider Buying and Selling

In other news, Director Kevin Tang purchased 200,000 shares of the company's stock in a transaction dated Tuesday, August 5th. The shares were purchased at an average price of $11.68 per share, for a total transaction of $2,336,000.00. Following the transaction, the director owned 11,329,500 shares of the company's stock, valued at approximately $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have purchased 1,300,000 shares of company stock worth $13,590,000. 12.20% of the stock is owned by company insiders.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock traded down $0.11 during midday trading on Tuesday, hitting $12.96. 382,355 shares of the company traded hands, compared to its average volume of 1,627,629. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of 30.13 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. The firm's fifty day moving average price is $11.28 and its 200-day moving average price is $9.18. Aurinia Pharmaceuticals Inc has a 12 month low of $6.55 and a 12 month high of $13.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). The company had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.